^
Association details:
| Biomarker: | SMAD4 deletion |
|---|---|
| Cancer: | Pancreatic Adenocarcinoma |
| Drug: | gemcitabine (DNA synthesis inhibitor) + albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor) + hydroxychloroquine (Immunomodulator, Phospholipase A2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma
Published date:
05/18/2021
Excerpt:
...a randomized trial of gemcitabine/nab-paclitaxel +/- HCQ evaluated...Twenty-five patients had SMAD4 loss (48%). 76% of HCQ-treated patients with SMAD4 loss obtained a histopathologic response greater than or equal to 2A, compared with only 37% with SMAD4 intact (p = 0.006)....The addition of HCQ to neoadjuvant chemotherapy in patients with PDA may improve treatment response in those with SMAD4 loss.
DOI:
https://doi.org/10.1111/cts.13029
Trial ID:
